First, we confirmed these data in a cohort (n = 42) of non-small cell lung carcinomas (NSCLCs) in which the tissue samples were sorted according to their Vimentin status: EMT+ tumors that exhibit high percentages of malignant cells expressing this biomarker and EMT− tumors with a complete absence of expression for this protein by the cancer cells [22]. This evidence concerns the gene VIM and cancer.